» Articles » PMID: 23253715

Progression of Solitary and Multifocal Papillary Thyroid Carcinoma - a Retrospective Study of 368 Patients

Overview
Specialty General Medicine
Date 2012 Dec 21
PMID 23253715
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Papillary thyroid carcinoma (PTC) represents one of the most frequent endocrine malignancies. Several factors have been found to be involved in determining the outcome of treatment for patients with PTC. Large tumor size, diagnosis at an early age, extra-thyroidal invasion, aggressive histological variants, and distant metastases are the most important determinants of a poor outcome. BRAF(V600E) mutation has been found to be a major genetic alteration in PTC. This study aimed to evaluate progression in patients with multifocal and solitary PTC.

Methods: We performed a retrospective study to analyze 368 patients with PTC who underwent surgery, including 282 patients with solitary PTC and 86 patients with multifocal PTC. The status of BRAF(V600E) mutation in all tumor foci from multifocal PTC was detected.

Results: Our study suggested that multifocal PTC was more related to lymph node metastasis and vascular invasion than solitary PTC. However, the distant metastasis rate and 10-year survival rate showed no difference between these two groups. The number of tumor foci did not affect progression of disease in multifocal PTC patients. Lymph node metastasis in multifocal PTC patients was associated with larger tumors, diagnosis at early stage, and extra-thyroidal invasion.

Conclusion: The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients with lymph node metastasis and diagnosis at later age.

Citing Articles

Genetic alterations landscape in paediatric thyroid tumours and/or differentiated thyroid cancer: Systematic review.

de Sousa M, Nunes I, Christiano Y, Sisdelli L, Cerutti J Rev Endocr Metab Disord. 2023; 25(1):35-51.

PMID: 37874477 DOI: 10.1007/s11154-023-09840-2.


Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Li J, Liang J, Zhao T, Lin Y Eur J Nucl Med Mol Imaging. 2016; 43(6):1034-9.

PMID: 26780618 DOI: 10.1007/s00259-015-3305-1.


The association between BRAF (V600E) mutation and pathological features in PTC.

Liu X, Yan K, Lin X, Zhao L, An W, Wang C Eur Arch Otorhinolaryngol. 2014; 271(11):3041-52.

PMID: 24389984 DOI: 10.1007/s00405-013-2872-7.